Biotech News

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma (ASND)Ascendis Pharma2026-04-20 12:00 ESTCompany update

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs).

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-08-13 11:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Stock data

Close: 253.29 USD
Market cap: 13.38B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Related news

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026